Arch Therapeutics’ Ac5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care Spring | Wound Healing Society
May 10, 2021 at 07:50 am EDT
Share
Arch Therapeutics, Inc. presents two clinical case reports supporting the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Spring this week. Both abstracts are available as Poster Presentations, and one abstract qualified for Podium Presentation in the Rapid Fire Symposium and earned a ribbon designation in the Poster Hall as the 2021 Highest Scoring Poster Abstract in the “Case Series/Study” category. AC5® Advanced Wound System received marketing authorization by the US Food and Drug Administration and is now commercially available. A comparable product, AC5® Topical Hemostat, received a CE mark in Europe. The clinical case reports presented at SAWC further confirm the effectiveness of AC5 Advanced Wound System in patients with significant comorbidities and prior failed treatments. The company's growing body of clinical data provides further support for use of AC5 Advanced Wound System as first-line therapy for patients with or at risk for stalled or chronic wounds. The following clinical case reports, which are now available online to all SAWC attendees, examine the use of the AC5® Advanced Wound System in patients with chronic and non-healing wounds: Rapid Healing of a Chronic Trophic Ulcer in a Patient with Peripheral Vascular and Autoimmune Comorbidities using a Novel Self-assembling Peptide-based Advanced Dressing Laura Pfendler PT DPT, Kalpana Kamath PhD, Daniel Wadsworth, Daniel Kapp MD. Poster #: CS-45. Poster Hall Ribbon Designation: 2021 Highest Scoring Poster Abstract Case Series/Study. Podium Presentation: May 11, 2021 4pm EDT. Conclusion: Complete healing of this recalcitrant trophic ulcer, which was unresponsive to multiple wound management regimens during the prior four years, was achieved with only three applications of AC5 in less than three weeks. The phenomenon was particularly impressive, considering the patient’s multiple vascular and autoimmune diseases, known to hinder the progression of wound healing and likely contributing to failure of prior wound-care regimens. Effective Management of a Non-healing Wound Post-Mohs Surgery using a Novel Self-assembling Peptide-based Advanced Wound Dressing. Laura Pfendler PT DPT, Kalpana Kamath PhD, Daniel Wadsworth, Daniel Kapp MD. Poster #: CS-44. Conclusion: Concomitant use of excisional debridement and treatment with AC5 markedly accelerated healing of this stalled wound, which had failed two months of standard therapy. The effect of AC5 may be attributed to the contiguous barrier it creates along the wound surface after debridement, in addition to its ability to promote cell adhesion, migration, and proliferation, which are essential for wound healing.
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.